Postnatal Instead of Normally-timed Cervical Screening (PINCS)

Investigating the acceptability and accuracy of cervical screening and self-sampling in women at 6-weeks postnatal - PINCS

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN10071810

Enrollment

100

Registered

2024-03-12

Start date

2024-06-11

Completion date

Unknown

Last updated

2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical screening Cancer

Interventions

To understand reasons for non-participation and establish an uptake rate, a sub-study cohort of 100 potential participants will all be approached and the acceptance rate recorded. The reason given by

Eligibility

Sex/Gender

Female

Age

24.5 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. 24.5 to 64 years 2. Has a uterine cervix and eligible for cervical screening 3. Currently pregnant or recently delivered 4. <6 weeks postpartum 5. Valid informed consent to cervical screening at 6 and 12 weeks postnatal

Exclusion criteria

Exclusion criteria: 1. <24.5 years old 2. Absence of uterine cervix or ineligible for cervical screening 3. Lack of valid informed consent to screening at 6 weeks postnatal

Design outcomes

Primary

Measure	Time frame
To evaluate the acceptability and feasibility of a paired study design 1. Acceptability: 1.1. Recruitment and completion rates of undergoing testing at 6 and 12 weeks in the study. 1.2. Acceptability will be measured via a patient-reported outcomes questionnaire following testing at 6 and 12 weeks postnatal, including a 10-point visual analogue pain scale 2. Feasibility: How many women need to be approached for one to consent? Measured using study records	—

Measure

Time frame

To evaluate the acceptability and feasibility of a paired study design 1. Acceptability: 1.1. Recruitment and completion rates of undergoing testing at 6 and 12 weeks in the study. 1.2. Acceptability will be measured via a patient-reported outcomes questionnaire following testing at 6 and 12 weeks postnatal, including a 10-point visual analogue pain scale 2. Feasibility: How many women need to be approached for one to consent? Measured using study records

—

Secondary

Measure	Time frame
1. Evaluate acceptability of clinician-taken cervical samples and urine self-screening tests in those who decline, in those who consent both at 6 and 12 weeks using questionnaire data (measured in a 100-patient sub-study of all of those approached about the study) 2. Assess the quality of cervical samples from clinician-taken samples at 6-weeks postnatal against standard NHS Cervical Screening Programme criteria 3. To determine the agreement in HR HPV status at 6- and 12-weeks postnatal between clinician-taken cervical samples and self-testing using urine tests (using a 2-by-2 table to test for sensitivity, specificity, negative and postitive predictive values)	—

Measure

Time frame

1. Evaluate acceptability of clinician-taken cervical samples and urine self-screening tests in those who decline, in those who consent both at 6 and 12 weeks using questionnaire data (measured in a 100-patient sub-study of all of those approached about the study) 2. Assess the quality of cervical samples from clinician-taken samples at 6-weeks postnatal against standard NHS Cervical Screening Programme criteria 3. To determine the agreement in HR HPV status at 6- and 12-weeks postnatal between clinician-taken cervical samples and self-testing using urine tests (using a 2-by-2 table to test for sensitivity, specificity, negative and postitive predictive values)

—

Countries

England, United Kingdom

Contacts

Public ContactVictoria Cullimore

PINCSStudy@somersetft.nhs.uk-

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Jul 23, 2026